P^(16)蛋白在肾癌组织中表达的临床评价  

Expression of P16 Protein in Renal Cell Carcinoma(RCC)

作　　者：张孝斌[1] 程帆[1] 金化民[1] 龚玲玲[2] 张晓毅 

机构地区：[1]湖北医科大学附属第一医院泌尿外科,武汉430060 [2]湖北医科大学附属第二医院病理科

出　　处：《肿瘤防治研究》1999年第6期447-448,共2页Cancer Research on Prevention and Treatment

摘　　要：采用免疫组织化学S-P法检测41例肾癌、18例癌旁正常肾组织及10例正常肾组织中P16蛋白的表达，以探讨P16蛋白表达与肾癌生物学行为的关系。结果发现：P16蛋白在肾癌及正常肾组织中的阳性表达率分别为58．5％（24／4）及89．3％（25／28），两组阳性表达具有显著性差异（X2=7．64，P＜0．05），P16蛋白表达在肾透明细胞癌及颗粒细胞癌间无差异，随肾癌分级、分期升高而明显降低，P16阳性表达组术后5年生存率明显高于阴性表达组。结果提示：P16基因失活在肾癌的发生发展中起重要作用，P16基因及蛋白的检测可作为肾癌的辅助诊断及预后判断的参考指标。Immunohistochemiwstry detection of P16 expression was carried out in 41 cases of renal careinoma, in 18 normal renal tissue adjacent to neoplastic lesions and in 10 normal renal tissue. The positive rates of P16 was higher in normal renal tissue(89. 3% ) than in tumor tissue(58. 5 % ) (P＜0.05 ), and cormlated with grading,staging and prognosis of patients, with no significant difference betWeen clear renal cell carcinoma and gIanulax cell carcinona. The results suggested that P16 played a critical role in the genesis and development of RCC and could be used as predictor of diagnosis and prognosis of renal carcinorna.

关 键 词：肾肿瘤 P16蛋白 免疫组织化学 基因表达 

分 类 号：R737.110.2[医药卫生—肿瘤]